TNF and psoriasis: Our findings may contribute to a better understanding of relatively low hospitalization rates in rheumatological patients treated with systemic drugs (although mainly with TNF-α inhibitors), who fell ill to COVID-19 and possibly explain why no significant increase in mortality or hospitalization was found for psoriasis patients under systemic treatment.